- Home
- CUZ vs RARE Comparison
CUZ vs RARE Comparison
Compare CUZ & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUZ
- RARE
- Stock Information
- Founded
- CUZ 1958
- RARE 2010
- Country
- CUZ United States
- RARE United States
- Employees
- CUZ N/A
- RARE N/A
- Industry
- CUZ Real Estate Investment Trusts
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- CUZ Real Estate
- RARE Health Care
- Exchange
- CUZ Nasdaq
- RARE Nasdaq
- Market Cap
- CUZ 4.4B
- RARE 5.2B
- IPO Year
- CUZ N/A
- RARE 2014
- Fundamental
- Price
- CUZ $30.61
- RARE $40.00
- Analyst Decision
- CUZ Buy
- RARE Strong Buy
- Analyst Count
- CUZ 8
- RARE 15
- Target Price
- CUZ $33.13
- RARE $92.00
- AVG Volume (30 Days)
- CUZ 1.4M
- RARE 1.1M
- Earning Date
- CUZ 02-06-2025
- RARE 02-13-2025
- Dividend Yield
- CUZ 4.18%
- RARE N/A
- EPS Growth
- CUZ N/A
- RARE N/A
- EPS
- CUZ 0.34
- RARE N/A
- Revenue
- CUZ $827,912,000.00
- RARE $522,745,000.00
- Revenue This Year
- CUZ N/A
- RARE $26.70
- Revenue Next Year
- CUZ $5.45
- RARE $19.02
- P/E Ratio
- CUZ $91.36
- RARE N/A
- Revenue Growth
- CUZ 3.09
- RARE 27.44
- 52 Week Low
- CUZ $21.58
- RARE $37.02
- 52 Week High
- CUZ $32.55
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- CUZ 53.82
- RARE 35.88
- Support Level
- CUZ $28.25
- RARE $39.79
- Resistance Level
- CUZ $30.44
- RARE $44.52
- Average True Range (ATR)
- CUZ 0.61
- RARE 2.20
- MACD
- CUZ 0.06
- RARE -0.08
- Stochastic Oscillator
- CUZ 75.88
- RARE 3.26
About CUZ Cousins Properties Incorporated
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. Cousins' assets are mainly located in Texas and Georgia, with North Carolina also playing host to a smaller amount of rental space. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.